{"id":5541,"date":"2022-10-05T07:31:55","date_gmt":"2022-10-05T14:31:55","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=5541"},"modified":"2022-10-05T07:32:02","modified_gmt":"2022-10-05T14:32:02","slug":"fda-evusheld-may-lack-efficacy-against-upcoming-covid-19-subvariants","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/10\/05\/fda-evusheld-may-lack-efficacy-against-upcoming-covid-19-subvariants\/","title":{"rendered":"FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"5541\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<p>Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.<\/p>\n\n\n\n<p>In the revised fact sheet, the FDA warned that providers should be aware of an increased risk for developing COVID-19 when exposed to certain COVID-19 variants that are not neutralized by\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.healio.com\/news\/rheumatology\/20220630\/fda-announces-new-evusheld-dosing-guidelines-shelflife-extension\" target=\"_blank\">tixagevimab packaged with cilgavimab (Evusheld, AstraZeneca)<\/a>.<br><a href=\"https:\/\/www.healio.com\/news\/rheumatology\/20221004\/fda-evusheld-may-lack-efficacy-against-upcoming-covid19-subvariants?utm_source=selligent&amp;utm_medium=email&amp;utm_campaign=news&amp;M_BT=7635131937835\">Read the full story<\/a> in Healio. <\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"5541\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2022\/10\/05\/fda-evusheld-may-lack-efficacy-against-upcoming-covid-19-subvariants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":872,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,42],"tags":[1137,1138,1135,1136],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1256","post_likes_plusCounter":"2","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5541"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=5541"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5541\/revisions"}],"predecessor-version":[{"id":5542,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/5541\/revisions\/5542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/872"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=5541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=5541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=5541"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=5541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}